A Pivotal Randomized Open-Label Study of Optune (TTFields 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 22 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of glioblastoma (GBM) according to WHO classification criteria. 2) Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection and biopsy-only patients are all acceptable). 3) Women of childbearing potential must have a negative Beta-HCG pregnancy test documented within 14 days prior to registration. 4) Is able to have MRI with contrast of the brain.

You may not be eligible for this study if the following are true:

  • 1) Progressive disease (per investigator's assessment). 2) lnfratentorial or leptomeningeal disease. 3) Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study. 4) Pregnancy or breast-feeding.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.